<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">AAPS J</journal-id><journal-title-group><journal-title>The AAPS Journal</journal-title></journal-title-group><issn pub-type="epub">1550-7416</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>Boston</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2751378</article-id><article-id pub-id-type="pmid">18454322</article-id><article-id pub-id-type="publisher-id">9028</article-id><article-id pub-id-type="doi">10.1208/s12248-008-9028-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Indolealkylamines: Biotransformations and Potential Drug&#x02013;Drug Interactions</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yu</surname><given-names>Ai-Ming</given-names></name><address><phone>+1-716-6452842</phone><fax>+1-716-6453693</fax><email>aimingyu@buffalo.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, 541 Cooke Hall, Buffalo, New York 14260-1200 USA </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>5</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>5</month><year>2008</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2008</year></pub-date><volume>10</volume><issue>2</issue><fpage>242</fpage><lpage>253</lpage><history><date date-type="received"><day>23</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; American Association of Pharmaceutical Scientists 2008</copyright-statement></permissions><abstract xml:lang="en"><p>Indolealkylamine (IAA) drugs are 5-hydroxytryptamine (5-HT or serotonin) analogs that mainly act on the serotonin system. Some IAAs are clinically utilized for antimigraine therapy, whereas other substances are notable as drugs of abuse. In the clinical evaluation of antimigraine triptan drugs, studies on their biotransformations and pharmacokinetics would facilitate the understanding and prevention of unwanted drug&#x02013;drug interactions (DDIs). A stable, principal metabolite of an IAA drug of abuse could serve as a useful biomarker in assessing intoxication of the IAA substance. Studies on the metabolism of IAA drugs of abuse including lysergic acid amides, tryptamine derivatives and &#x003b2;-carbolines are therefore emerging. An important role for polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP2D6 polymorphism may represent an additional risk factor in the use of these IAA drugs. Furthermore, DDIs with IAA agents could occur additively at the pharmaco/toxicokinetic and dynamic levels, leading to severe or even fatal serotonin toxicity. In this review, the metabolism and potential DDIs of these therapeutic and abused IAA drugs are described.</p></abstract><kwd-group><title>Keywords</title><kwd>CYP2D6</kwd><kwd>drug interactions</kwd><kwd>indolealkylamine</kwd><kwd>metabolism</kwd><kwd>MAO</kwd><kwd>pharmacogenetics</kwd><kwd>tryptamine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; American Association of Pharmaceutical Scientists 2008</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>INTRODUCTION</title><p>Indolealkylamines (IAAs) are chemical derivatives of 5-hydroxytryptamine (5-HT or serotonin), a monoamine neurotransmitter that modulates human mood and behaviors. Structurally, these compounds all possess an indole moiety and a basic nitrogen atom, which are connected by an alkyl chain usually of two carbons in length. Acting on the serotonergic system, some IAA agents such as ergotamine and triptan drugs (e.g. sumatriptan, naratriptan and almotriptan) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) have been successfully developed for antimigraine therapy (<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>).
<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Chemical structures of the 5-HT neurotransmitter and some antimigraine triptan drugs</p></caption><graphic xlink:href="12248_2008_9028_Fig1_HTML" id="MO1"/></fig></p><p>Many other IAA agents are important as widely abused substances although some show potential in psychopharmacotherapy. This group of IAA agents consists of lysergic acid amides such as <sc>d</sc>-lysergic acid diethylamide (LSD) and ergine (LSA), tryptamines such as psilocybin, <italic>N</italic>,<italic>N</italic>-dimethyltryptamine (DMT), bufotenine, 5-methoxy-<italic>N</italic>,<italic>N</italic>-dimethyltryptamine (5-MeO-DMT) and 5-methoxy-<italic>N</italic>,<italic>N</italic>-diisopropyltryptamine (5-MeO-DIPT), and &#x003b2;-carbolines such as harman, harmaline and harmine (<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Tryptamine (e.g. 5-MeO-DMT) and &#x003b2;-carboline (e.g. harmaline) derivatives are sometimes abused together. These substances are readily synthesized in underground laboratories, sold via the internet and abused particularly by teenagers and young adults. As an unscheduled substance, 5-MeO-DMT has even been referred to as the next generation designer drug to replace &#x0201c;ecstasy.&#x0201d; Cases of IAA intoxication have been continuously documented in the United States (<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>). Overdosing or combined abuse of IAA agents may cause severe or even fatal hyperserotonergic toxicity, namely &#x0201c;serotonin syndrome&#x0201d; (<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref>). Of note, serotonin toxicity has become an important clinical problem over the last 15&#x000a0;years with the increasing use of psychotropic agents.
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Chemical structures of some indolealkylamine drugs of abuse that consist of <sc>d</sc>-lysergic acid amides (e.g. LSD and LSA), tryptamine derivatives (e.g. psilocybin, DMT, bufotenine, 5-MeO-DMT and 5-MeO-DIPT), &#x003b2;-carbolines (e.g. harman, harmaline and harmine) and ibogaine</p></caption><graphic xlink:href="12248_2008_9028_Fig2_HTML" id="MO2"/></fig></p><p>A substantial body of research has revealed considerable variations in the metabolic and pharmacokinetic properties for therapeutic triptan agents, and provided adequate data to predict metabolic drug&#x02013;drug interactions (DDIs) in clinical practice. In contrast, the metabolism of IAA drugs of abuse has not been fully characterized because of legal, ethical and safety issues associated in conducting human tests. For these agents, a stable metabolite, measured by a reliable analytical method, may serve as a better approach for forensic analysis. Many metabolic data were therefore obtained from animal studies, in which the discrepancy is obvious for some drugs (<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>). Furthermore, the specific role of individual drug-metabolizing enzymes including monoamine oxidases (MAO) and cytochrome P450 (P450 or CYP) enzymes (<xref ref-type="bibr" rid="CR14">14</xref>) remains undefined, and mechanistic understanding of potential DDIs with other abused or therapeutic agents is mostly unknown. Increased knowledge in this area may advance our understanding of individual vulnerability to and/or protection from illicit drugs of abuse (<xref ref-type="bibr" rid="CR15">15</xref>). This review, therefore, aims to describe our current understanding of the metabolism and potential DDIs of IAA drugs.</p></sec><sec id="Sec2"><title>METABOLISM AND DRUG&#x02013;DRUG INTERACTIONS OF THERAPEUTIC INDOLEALKYLAMINE DRUGS</title><sec id="Sec3"><title>Mechanisms of Indolealkylamine Drugs for Antimigraine Therapy</title><p>Ergotamine remains as a useful drug for acute treatment of severe migraine attacks (<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR16">16</xref>). It is an ergot alkaloid originally isolated from fungus, and its pharmacological property in relieving migraine headache was shown about 70&#x000a0;years ago. Its antimigraine effect is generally attributed to the actions on 5-HT1B/1D receptors, whereas its side effects may be caused by the nonselective actions on a variety of other receptors including dopamine and 5-HT1A receptors.</p><p>In contrast to the complex mode of actions of ergotamine, newer IAA antimigraine drugs, namely triptans, are much more selective for 5-HT1B and 5-HT1D receptors with high affinity (<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>). Sumatriptan is the first of these &#x0201c;new generation&#x0201d; IAA antimigraine agents that are better tolerated by patients. The pharmacokinetics properties of these triptans are quite diverse. For instance, the oral bioavailability of sumatriptan is about 14% whereas naratriptan is 63&#x02013;74%. The elimination half-life of sumatriptan is 2&#x000a0;h whereas for frovatriptan, it is 25&#x000a0;h (Table <xref rid="Tab1" ref-type="table">I</xref>). The sharp difference in elimination of different triptans is at least partly due to the marked difference in the metabolism of these drugs.
<table-wrap id="Tab1"><label>Table&#x000a0;I</label><caption><p>Comparative Overview of the Metabolic and Pharmacokinetic Data of Triptan Drugs</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Triptan drug</th><th>Oral bioavailability (%)</th><th><italic>T</italic><sub>1/2</sub> (h)</th><th>Major metabolic pathway</th><th>Dominant enzyme</th><th>Active metabolite</th></tr></thead><tbody><tr><td>Sumatriptan</td><td>~14</td><td>~2</td><td>Deamination</td><td>MAO-A</td><td>No</td></tr><tr><td>Zolmitriptan</td><td>~40</td><td>~3</td><td>N-Demethylation</td><td>CYP1A2</td><td>Yes</td></tr><tr><td>Naratriptan</td><td>74 (female), 63 (male)</td><td>~6</td><td>Not reported</td><td>P450s</td><td>No</td></tr><tr><td>Rizatriptan</td><td>~47</td><td>2&#x02013;2.5</td><td>Deamination</td><td>MAO-A</td><td>No</td></tr><tr><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td><td>N-demethylation</td><td>P450s</td><td>Yes</td></tr><tr><td>Eletriptan</td><td>~50</td><td>4&#x02013;5</td><td>N-Demethylation</td><td>CYP3A4</td><td>Yes</td></tr><tr><td>Almotriptan</td><td>~70</td><td>~3.6</td><td>Deamination</td><td>MAO-A </td><td>No</td></tr><tr><td>&#x000a0;</td><td>&#x000a0;</td><td>&#x000a0;</td><td>Hydroxylation</td><td>CYP3A4/2D6</td><td>&#x000a0;</td></tr><tr><td>Frovatriptan</td><td>30 (female), 24 (male)</td><td>~25</td><td>N-Demethylation and hydroxylation</td><td>CYP1A2</td><td>No</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Metabolism and Drug&#x02013;Drug Interactions of Ergotamine and Triptans</title><p>Although ergotamine is known to be extensively metabolized in the liver, its metabolic pathways are largely undefined in humans. Nonetheless, there is good evidence from animal studies supporting that CYP3As are the major enzymes responsible for ergotamine metabolism (<xref ref-type="bibr" rid="CR17">17</xref>). Indeed, CYP3A inhibitory drugs such as erythromycin and troleandomycin are known to decrease ergotamine metabolism and may lead to unwanted DDIs. To prevent such metabolic DDIs and potentially adverse drug effects, concomitant use of ergotamine with CYP3A4 inhibitory drugs should be avoided.</p><p>Deamination metabolism is the predominant pathway for sumatriptan (<xref ref-type="bibr" rid="CR18">18</xref>) and rizatriptan (<xref ref-type="bibr" rid="CR19">19</xref>), and a major route for almotriptan (<xref ref-type="bibr" rid="CR20">20</xref>). MAO-A is the principal enzyme responsible for initiating the biotransformation (Table <xref rid="Tab1" ref-type="table">I</xref>). Their end metabolites, indole acetic acids, are inactive and can be readily recovered in urine. For instance, 50% of orally administered and 35% of intravenously administered (14)C-rizatriptan was excreted as triazolomethyl-indole acetic acid in human urine (<xref ref-type="bibr" rid="CR19">19</xref>). As expected, concurrent administration of MAO-A inhibitors such as moclobemide may decrease the clearance of these triptans and increase the systemic exposure (<xref ref-type="bibr" rid="CR20">20</xref>).</p><p>The other major pathway for almotriptan metabolism is hydroxylation, which is catalyzed mainly by CYP3A4 and CYP2D6 (<xref ref-type="bibr" rid="CR20">20</xref>). In addition to deamination inactivation, rizatriptan undergoes N-oxygenation, 6-hydroxylation and N-demethylation (<xref ref-type="bibr" rid="CR19">19</xref>). The <italic>N</italic>-monodesmethyl-rizatriptan, formed to a minor degree, exhibits similar pharmacological activity as the parent drug at the 5-HT1B/1D receptors. In contrast, 6-hydroxy-rizatriptan and the <italic>N</italic>-oxide produced by phase I drug-metabolizing enzymes are not active at the 5-HT1B/1D receptors.</p><p>N-Demethylation is the main metabolic pathway for zolmitriptan (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), eletriptan and frovatriptan. CYP1A2 is the major enzyme mediating N-demethylation of zolmitriptan (<xref ref-type="bibr" rid="CR21">21</xref>) and frovatriptan (<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref>), and CYP3A4 is the primary enzyme catalyzing N-demethylation of eletriptan (<xref ref-type="bibr" rid="CR24">24</xref>). <italic>In vitro</italic> studies have also revealed that CYP3A4 inhibitors can significantly reduce eletriptan N-demethylation (<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref>). Because zolmitriptan is primarily excreted via this oxidative metabolic route, CYP1A2 inhibitors and inducers are expected to significantly alter the clearance and systemic exposure of zolmitriptan (<xref ref-type="bibr" rid="CR21">21</xref>). In contrast, the CYP1A2 inhibitor fluvoxamine has been shown to have minor effects on frovatriptan pharmacokinetics, primarily because frovatriptan is significantly eliminated by renal clearance (<xref ref-type="bibr" rid="CR22">22</xref>).
<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Biotransformation of an antimigraine triptan drug, zolmitriptan. CYP1A2, cytochrome P450 1A2; MAO-A, monoamine oxidase A; ALDH, aldehyde dehydrogenase</p></caption><graphic xlink:href="12248_2008_9028_Fig3_HTML" id="MO3"/></fig></p><p>In contrast to the inactive <italic>N</italic>-desmethyl-frovatriptan, the N-demethylated metabolites from zolmitriptan and eletriptan are both active at the 5-HT1B/1D sites. In particular, the <italic>N</italic>-desmethyl-zolmitriptan acts on 5-HT1B/1D receptors with an affinity about two- to six-fold of that of zolmitriptan and its steady state concentration is also higher than the parent drug. Therefore, <italic>N</italic>-desmethyl-zolmitriptan may have important contribution to the overall zolmitriptan drug effects. This active metabolite undergoes selective MAO-A-mediated deamination metabolism, resulting in an inactive indole acetic acid derivative (<xref ref-type="bibr" rid="CR21">21</xref>) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Because zolmitriptan is extensively N-demethylated and <italic>N</italic>-desmethyl-zolmitriptan is primarily excreted via deamination, potent MAO-A inhibitors are anticipated to alter the pharmacokinetics of <italic>N</italic>-desmethyl-zolmitriptan in humans. Indeed, concurrent use of selective MAO-A inhibitor, moclobemide, has been shown to cause 1.5- to 3-fold increase in the systemic exposure (AUC) and peak drug concentration (Cmax) of <italic>N</italic>-desmethyl-zolmitriptan (<xref ref-type="bibr" rid="CR25">25</xref>).</p><p>Additionally, some N-demethylated triptan metabolites may be further hydroxylated or N-acetylated (e.g. frovatriptan), and a small portion of the parent triptans may be converted to N-oxide (e.g. zolmitriptan by CYP1A2; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). These information may aid our understanding of the pharmacokinetics of triptans and in predicting their unwanted metabolic DDIs.</p></sec></sec><sec id="Sec5"><title>METABOLISM AND DRUG&#x02013;DRUG INTERACTIONS OF INDOLEALKYLAMINE DRUGS OF ABUSE</title><sec id="Sec6"><title>Widespread Abuse of Indolealkylamine Drugs</title><p>Since the discovery of hallucinogenic properties for LSD (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), which include the alteration and distortion of human perceptions, this agent has been used by millions of people in the United States and elsewhere for quasi-religious and recreational purposes. Other psychedelic IAA drugs of abuse include psilocybin, DMT, bufotenine, 5-MeO-DMT, 5-MeODIPT, harman, harmine, harmaline and ibogaine (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) that are all 5-HT analogs.</p><p>Many IAAs have been found to be the psychoactive ingredients of a wide range of plant, fungus and animal preparations, which have been used in social and religious cultures in history. 5-MeO-DMT and bufotenine are the major ingredients of the venom of psychoactive toads such as Colorado River <italic>Bufo alvarius</italic> (<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref>). 5-MeO-DMT is also the psychoactive agent in numerous plant preparations including Virola snuffs. Harmaline, harmine, tetrahydroharmine and DMT are important active constituents of the beverage Ayahuasca (<xref ref-type="bibr" rid="CR28">28</xref>). Several methylated IAAs have been detected as endogenous compounds in humans. 5-MeO-DMT can be synthesized in human pineal gland and has been detected in both pineal gland and urine (<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>). The methylated IAAs are also present in retina at relatively high levels (<xref ref-type="bibr" rid="CR32">32</xref>). Derived from 5-HT through methylation (methylated IAAs) and Pictet&#x02013;Spengler condensation (&#x003b2;-carbolines), the presence of these psychedelic IAAs in humans is certainly clear. Although their biological roles and association with psychiatric diseases are still obscure, increased understanding of their metabolic pathways (<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref>) would be helpful in answering these questions.</p><p>Presently, IAA drugs are readily synthesized in clandestine laboratories and sold via the internet. Studies by Monitoring the Future programs (<xref ref-type="bibr" rid="CR35">35</xref>) have revealed that, in every year since 1991 to 2006, more than 8.3% of 12th-graders have used hallucinogens. The abuse of hallucinogenic substance other than LSD remains over 8.0% since 2001. Additionally, nearly 50% of teenagers surveyed since 2001 said that it was &#x0201c;fairly easy&#x0201d; or &#x0201c;very easy&#x0201d; to get hallucinogens other than LSD. As a presently unscheduled hallucinogen, 5-MeO-DMT has been suggested as the next generation designer drug to replace &#x0201c;ecstasy&#x0201d; and it is often used in combination with harmaline (also an unscheduled substance in the USA). Intoxications due to IAA drugs have been frequently reported in hospitals in recent years (<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>).</p><p>These psychoactive IAA agents have also shown some therapeutic value in treating mental health disorders. For instance, ayahuasca may be utilized for the treatment of alcoholism, serotonergic defects and substance abuse (<xref ref-type="bibr" rid="CR28">28</xref>), and ibogaine for cocaine addiction (<xref ref-type="bibr" rid="CR36">36</xref>). Indeed, IAAs act on a variety of 5-HT receptors, serotonin transporter, or MAO enzyme that are highly favorable molecular targets for treating depression, anxiety, schizophrenia, and other psychiatric disturbances (<xref ref-type="bibr" rid="CR37">37</xref>). Nevertheless, medical use of these agents remains a challenge because IAA drug responses exhibit considerable variability in humans (<xref ref-type="bibr" rid="CR38">38</xref>), and concerns about their safety and abuse liability persist (<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR39">39</xref>).</p></sec><sec id="Sec7"><title>Mechanisms of Action of Indolealkylamine Drugs of Abuse</title><p>LSD was thought initially to act through 5-HT antagonism in the central nervous system or through mimicry of 5-HT actions by interacting with the 5-HT receptor. After 5-HT was firmly established as a neurotransmitter, it was found that LSD inhibited the activity of serotonergic neurons. With the delineation of 5-HT receptor subtypes and the extension of serotonergic actions to other hallucinogenic agents, Glennon <italic>et al.</italic> (<xref ref-type="bibr" rid="CR40">40</xref>) established an excellent correlation between the hallucinogenic potency and the affinity of IAAs for 5-HT2 receptors. Collective evidence from biochemical, physiological and behavioral tests suggests that these hallucinogens likely act on a common site of 5-HT2A and other 5-HT2 receptors in the central nervous system (<xref ref-type="bibr" rid="CR5">5</xref>).</p><p>The pharmacological and toxicological effects of 5-MeO-DMT, however, were believed to act through the 5-HT1A receptor, as supported by results summarized by Winter <italic>et al.</italic> (<xref ref-type="bibr" rid="CR41">41</xref>). Furthermore, the inhibition of MAO enzyme or 5-HT uptake was thought to be important for the actions of &#x003b2;-carbolines such as harmaline in its induction of hypothermia (<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref>). The hallucinogenic effects of harmaline are likely produced from binding to 5-HT2A and 5-HT2C receptors, and the tremorgenic properties are due to the interactions with benzodiazepine receptors (<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>). Because harmaline stimulates locus coeruleus neuronal activity, it was even proposed as an endogenous ligand for imidazoline receptors (<xref ref-type="bibr" rid="CR47">47</xref>).</p><p>Hallucinations (e.g. colorful and luminous patterns) are characteristics for IAA intoxication in humans (<xref ref-type="bibr" rid="CR26">26</xref>). Distorted perception of time or auditory effects may also occur. In animals, IAA drugs (e.g. harmaline that is discussed above) are known to cause a variety of drug effects including physiological (e.g. body temperature), biochemical (e.g. monoamine neurotransmitters), and behavioral (e.g. discriminative control) changes. Despite some exceptions (<xref ref-type="bibr" rid="CR48">48</xref>), there is a strong correlation between the discriminative stimulus effects in non-verbal species and subjective effects in humans (<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>).</p><p>There are significant variations of drug effects for individual IAA agents in humans (<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR38">38</xref>). Some individuals can be adversely affected by IAA drugs including LSD, 5-MeO-DMT, bufotenine, and harmaline, some may not have any response, and yet others would use them with impunity. Meanwhile, depending upon the doses, 5-MeO-DMT may induce hypothermic or hyperthermic effects in animals (<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref>). Unfortunately, a clear understanding of the molecular basis and the vulnerability to IAA substances is still lacking.</p></sec><sec id="Sec8"><title>Metabolism of Indolealkylamine Drugs of Abuse</title><sec id="Sec9"><title>Metabolism of <sc>d</sc>-Lysergic Acid Diethylamide</title><p>LSD is extensively metabolized in laboratory animals and only a trivial fraction of the parent drug is excreted in urine. Major metabolites of LSD detected in the rat and guinea pig urines were the 13- and 14-hydroxy-LSD (HO-LSD) and their corresponding glucuronic acid conjugates (<xref ref-type="bibr" rid="CR54">54</xref>). Other metabolites included 2-oxo-LSD, lysergic acid ethylamide (LSE) and <italic>N</italic>-desmethyl-LSD (nor-LSD). In the isolated perfused rat liver, aromatic hydroxylation was shown as the principal metabolic pathway (<xref ref-type="bibr" rid="CR55">55</xref>). However, studies on LSD metabolism in rat liver microsomes indicated that nor-LSD and LSE were the major metabolites, followed by 13-hydroxy-LSD (<xref ref-type="bibr" rid="CR56">56</xref>). The metabolism of LSD was more complex in rhesus monkey because the urine consisted of at least nine metabolites. In contrast to the metabolism in rats and guinea pigs, aromatic hydroxylation was a minor metabolic pathway in rhesus monkey (<xref ref-type="bibr" rid="CR54">54</xref>). Thus, significant difference in LSD metabolism between humans and laboratory animals has been observed.</p><p>Indeed, at least four metabolites have been identified in urine from human users of LSD, which include 2-oxo-3-hydroxy-LSD (2-oxo-3-HO-LSD), nor-LSD, 13- and 14-hydroxy-LSD glucuronides (<xref ref-type="bibr" rid="CR57">57</xref>) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Although other metabolites such as LSE were produced as major metabolites from LSD incubated with human liver microsomes (<xref ref-type="bibr" rid="CR58">58</xref>), 2-oxo-3-HO-LSD was shown to be the main human urinary metabolite, which may be present at 4- to 41-times higher concentration than urinary LSD (<xref ref-type="bibr" rid="CR59">59</xref>). This metabolite therefore holds promise as a biomarker for LSD use in the forensic toxicology laboratories.
<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Metabolism of LSD. Note that the 2-oxo-3-hydroxy-LSD (<italic>2-oxo-3-HO-LSD</italic>) has been shown as a principal metabolite in the LSD-positive human urine samples</p></caption><graphic xlink:href="12248_2008_9028_Fig4_HTML" id="MO4"/></fig></p><p>The detection of 2-oxo-LSD in human body fluids indicates that 2-oxo-3-HO-LSD may be formed in two steps via the 2-oxo-LSD intermediate. Recent studies on LSD metabolism in human liver microsomes and hepatocytes not only confirmed the formation of 2-oxo-3-HO-LSD but also identified a 2,3-dihydroxy-LSD metabolite (<xref ref-type="bibr" rid="CR60">60</xref>). This finding suggests that 2-oxo-3-HO-LSD could be produced through dehydrogenation of the 2,3-dihydroxy-LSD intermediate, which is presumably formed from LSD 2,3-epoxide.</p><p>Due to limited studies on LSD metabolism in humans, further well-controlled studies are warranted to validate whether 2-oxo-3-HO-LSD is indeed the major metabolite (<xref ref-type="bibr" rid="CR59">59</xref>) and to delineate the particular mechanisms that are involved in the formation of this metabolite (<xref ref-type="bibr" rid="CR60">60</xref>). Furthermore, almost nothing is known regarding the contribution of specific drug-metabolizing enzyme to the production of individual LSD metabolites in humans. Advance in these areas could facilitate forensic detection, as well as the prediction and prevention of potential metabolic DDIs between LSD and other substances.</p></sec><sec id="Sec10"><title>Metabolism of Tryptamine Derivatives</title><p>Like tryptamine itself (<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR61">61</xref>), tryptamine derivatives including DMT, bufotenine and 5-MeO-DMT are excreted primarily via oxidative deamination and a predominant role for MAO-A is certain in this metabolic pathway (<xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR66">66</xref>). However, there are some discrepancies among animal studies reported in the literature. Sitaram&#x02019;s group (<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref>) showed that DMT and 5-MeO-DMT were metabolized through deamination, N-demethylation, O-demethylation, and N-oxygenation, and found that <italic>N</italic>-oxides were the major metabolites in rat tissues. In contrast, oxidative deamination and O-demethylation (followed by glucuronidation or deamination) were shown to be the major pathways for (14)C-labeled 5-MeO-DMT in rats (<xref ref-type="bibr" rid="CR12">12</xref>). Our <italic>in vitro</italic> studies using human liver microsomes, hepatocytes and recombinant enzymes agreed with the importance of deamination for 5-MeO-DMT metabolism, while 5-MeO-DMT was shown to be O-demethylated primarily by CYP2D6 (<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR69">69</xref>) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>), a P450 enzyme that has enormous genetic variations and is well recognized for its clinical importance (<xref ref-type="bibr" rid="CR70">70</xref>).
<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Deamination of bufotenine and 5-MeO-DMT produces corresponding indole acetic acid derivatives. 5-MeO-DMT can be biotransformed to bufotenine through O-demethylation catalyzed primarily by CYP2D6, whereas bufotenine may be methylated to form 5-MeO-DMT</p></caption><graphic xlink:href="12248_2008_9028_Fig5_HTML" id="MO5"/></fig></p><p>5-MeO-DMT O-demethylation is potentially an activation process because the metabolite bufotenine is a biologically active agent. Although the psychedelic activity for bufotenine has been questioned (<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR71">71</xref>), the confusion probably arises due to its poor lipid solubility. A variety of biochemical studies (<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR72">72</xref>) supported the hypothesis that bufotenine was a potent ligand at the 5-HT2A receptor with an affinity up to ten-fold higher than 5-MeO-DMT. Vogel and Evans (<xref ref-type="bibr" rid="CR73">73</xref>) estimated that bufotenine was about three times more potent than 5-MeO-DMT within the brain. Other studies also indicated that bufotenine was psychoactive in humans, as summarized by Ott (<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref>). It is interesting to note that bufotenine (the metabolite) is currently listed as a Schedule I controlled substance, whereas 5-MeO-DMT (its parent compound) is not. On the other hand, bufotenine may be converted to 5-MeO-DMT <italic>in vivo</italic> by methyltransferase (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p>5-MeO-DIPT is also an abused tryptamine derivative, which contains <italic>N</italic>,<italic>N</italic>-diisopropyl groups, rather than the <italic>N</italic>,<italic>N</italic>-dimethyl groups within 5-MeO-DMT. The metabolism of 5-MeODMT <italic>vs.</italic> 5-MeO-DIPT can be compared (<xref ref-type="bibr" rid="CR74">74</xref>). Analyses of urine samples collected from 5-MeO-DIPT users (<xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref>) suggested that this drug was mainly excreted via metabolism, in particular, O- and N-dealkylation and deamination (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). Because isotope-labeled 5-MeO-DIPT was not used and 5-HO-indole acetic acid is intrinsically present in human urine, it is unclear which pathway is the predominant route. Nonetheless, extensive studies using human liver microsomes and recombinant enzymes (<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR78">78</xref>,<xref ref-type="bibr" rid="CR79">79</xref>) revealed that CYP2D6 was responsible for 5-MeO-DIPT O-dealkylation, while CYP1A2, 3A4, 2C19 enzymes mediated its N-dealkylation. The critical role for CYP2D6 in 5-MeO-DIPT O-dealkylation might provide a reasonable explanation for the sharp difference in urinary 5-hydroxy-<italic>N</italic>,<italic>N</italic>-diisopropyltryptamine (5-HO-DIPT) level that was observed between Caucasian and Japanese drug users (<xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR77">77</xref>), if that Caucasian 5-MeO-DIPT user were to have deficient CYP2D6 activity and the Japanese user have regular CYP2D6 activity. Furthermore, 5-MeO-DIPT was mainly O-dealkylated in human liver microsomes, whereas it was primarily N-dealkylated in rat liver microsomes (<xref ref-type="bibr" rid="CR78">78</xref>,<xref ref-type="bibr" rid="CR79">79</xref>). The sharp species difference in region-selective metabolism of 5-MeO-DIPT, which is not unusual in drug metabolism (<xref ref-type="bibr" rid="CR80">80</xref>), may add complexity in the extrapolation of animal data to humans.
<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Metabolism of 5-MeO-DIPT. The O-demethylation is primarily mediated by CYP2D6 and N-deisopropylation is catalyzed by CYP1A2, 2C8, 2C9, 2C19 and 3A4</p></caption><graphic xlink:href="12248_2008_9028_Fig6_HTML" id="MO6"/></fig></p><p>Different from the tryptamine derivatives discussed above, psilocybin and psilocin are 4-substituted IAA drugs that have been found in many psychedelic mushrooms worldwide. Psilocin was readily detected in the blood and urine from human subjects taken psilocybin (<xref ref-type="bibr" rid="CR81">81</xref>). The dephosphorylation of psilocybin to produce psilocin (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>) appears to be an activation process. Identification of other metabolites including 4-hydroxyindole acetic acid (4-HO-IAA) and 4-hydroxyindole acetaldehyde suggested that psilocin underwent deamination oxidation. Additionally, the 4-hydroxy group of psilocin may be conjugated to form an <italic>O</italic>-glucuronide (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). In spite of these information, limited studies on the metabolism of psilocybin and psilocin have been reported, and specific enzymes that catalyze the formation of individual metabolites remain unknown.
<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Biotransformations of psilocybin and psilocin. Psilocybin is dephosphorylated to produce psilocin that undergoes deamination and glucuronidation</p></caption><graphic xlink:href="12248_2008_9028_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec11"><title>Metabolism of &#x003b2;-Carbolines and Ibogaine</title><p>&#x003b2;-Carbolines were shown to be good substrates for <italic>N</italic>-methyltransferase and the corresponding cation products were highly neurotoxic (<xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR83">83</xref>). In contrast, hydroxylation and O-demethylation of &#x003b2;-carboline alkaloids, followed by glucuronidation and sulfation, are expected to be detoxification processes that may play an important role in protection against brain damage.</p><p>The metabolism of harmine is relatively well understood, which includes two major oxidative pathways, O-demethylation and 6-hydroxylation (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>). Hydroxylation could also occur at the 3- or 4-position of harmine (<xref ref-type="bibr" rid="CR84">84</xref>). Hydroxyl &#x003b2;-carboline metabolites such as harmol are readily conjugated through glucuronidation and sulfation. The formation of harmol from harmine exhibited three- to four-fold higher Vmax in phenobarbitone-induced mouse liver microsomes (<xref ref-type="bibr" rid="CR85">85</xref>). Our recent study revealed that harmine O-demethylation was catalyzed by human CYP2D6, 1A1, 1A2, 2C9 and 2C19 enzymes (<xref ref-type="bibr" rid="CR86">86</xref>). Furthermore, we found that CYP2D6 was a major enzyme mediating the O-demethylation of harmaline and pinoline (<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR86">86</xref>), suggesting an important role for CYP2D6 in O-demethylation of these &#x003b2;-carbolines, although its role in their total clearance has not been determined yet. Given the fact that defect of CYP2D6 can significantly alter the pharmacokinetics of CYP2D6 substrate drugs, distinct pharmacokinetics may occur for these &#x003b2;-carbolines due to different CYP2D6 status. Indeed, a recent study (<xref ref-type="bibr" rid="CR87">87</xref>) disclosed that there were two phenotypes in harmine pharmacokinetics, fast and slow metabolism, in humans. Further investigation will determine whether this is because of CYP2D6 polymorphism, and whether this would be translated into significant difference in drug responses.
<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Metabolism of harmine. One major pathway is O-demethylation mediated by CYP2D6, 1A and 2C enzymes, and the metabolite harmol is subject to glucuronidation and sulfation. Hydroxylated harmine metabolites have also been identified, which occur at the 6- and 3- or 4-positions of harmine</p></caption><graphic xlink:href="12248_2008_9028_Fig8_HTML" id="MO8"/></fig></p><p>Little is known for many other &#x003b2;-carbolines regarding the specific enzymes that contribute to their biotransformation, although some of them have been shown to undergo aromatic hydroxylations. The depletion of harman in mouse liver microsomes was enhanced about 4- and 11-fold when pretreated with phenobarbitone and 3-methylcholanthrene, respectively. The major metabolite was found to be 6-hydroxyharman the formation of which was likely mediated by P450 enzymes (<xref ref-type="bibr" rid="CR88">88</xref>), but it is unclear which particular isozyme is involved. Interestingly, species difference was also shown in the metabolism of tetrahydroharman (1-methyl-1,2,3,4-tetrahydro-&#x003b2;-carboline). <italic>In vitro</italic> and <italic>in vivo</italic> studies demonstrated that tetrahydroharman was hydroxylated at the 5-, 6- and 7-positions in rats (<xref ref-type="bibr" rid="CR89">89</xref>), whereas it was mainly hydroxylated at the 6- and 7-positions in humans (<xref ref-type="bibr" rid="CR90">90</xref>,<xref ref-type="bibr" rid="CR91">91</xref>). Furthermore, 6-hydroxytetrahydroharman was present in both free and conjugated forms, and 7-hydroxytetrahydroharman mainly exist as a conjugated form in the urine from humans administered with deuterated tetraharman.</p><p>Ibogaine is an indole alkaloid initially isolated from a rain forest shrub, Tabernanthe Iboga, which is native to Africa. It is a schedule I substance in the United States while its potential as a pharmacotherapeutic agent in treating cocaine and opiate addictions has been explored recently (<xref ref-type="bibr" rid="CR36">36</xref>). Even in a Phase I trial containing a limited number of human subjects, ibogaine exhibited considerable variability in the pharmacokinetics of parent drug and its major metabolite, noribogaine (<xref ref-type="bibr" rid="CR92">92</xref>). CYP2D6 was subsequently identified as the predominant enzyme that catalyzed the formation of noribogaine from ibogaine (<xref ref-type="bibr" rid="CR93">93</xref>). Furthermore, noribogaine is pharmacologically active and has a similar pharmacodynamic profile as the parent drug with higher affinities to the opioid receptors and serotonin transporter. An important contribution of noribogaine to the overall ibogaine drug effects and the involvement of CYP2D6 polymorphism would also add complexity in the use of ibogaine.</p></sec></sec><sec id="Sec12"><title>Potential Drug&#x02013;Drug Interactions of Indolealkylamine Drugs of Abuse</title><p>DDIs occur at the pharmacokinetic level when one drug (perpetrator) alters the absorption, distribution, metabolism or excretion of another drug (victim) and at the pharmacodynamic level when the perpetrator and victim drugs work on the common targets (e.g. receptors) of action. Severe or fatal adverse reactions could be induced when pharmacokinetic and pharmacodynamic DDIs arise together additively. This may be true for IAA drugs that are abused concomitantly, in particular, through the use of a tryptamine derivative (e.g. 5-MeO-DMT) and a &#x003b2;-carboline (e.g. harmaline). First, harmaline itself possesses psychotropic activities, which not only inhibits MAO-mediated 5-HT degradation but also acts directly on 5-HT receptors (<xref ref-type="bibr" rid="CR46">46</xref>). Concomitant use of such MAO inhibitor and 5-HT agonist would potentiate serotonergic neurotransmission (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>). Second, by inhibiting MAO-A activity, harmaline is anticipated to reduce 5-MeO-DMT metabolic disposition, leading to an increased and prolonged exposure to 5-MeO-DMT. Additionally, the inhibition of MAO-A activity may shunt 5-MeO-DMT deamination to O-demethylation and results in elevated levels of the psychoactive metabolite bufotenine, the formation of which will depend on CYP2D6 status. A contribution of both 5-HT2A and 5-HT1A receptors to the overall 5-MeO-DMT drug effects is possible, and increased levels of bufotenine may even convert 5-MeO-DMT (5-HT1A) dominant effects to bufotenine (5-HT2A agonist) dominant effects. Such complex DDIs among IAA drugs and the involvement of CYP2D6 pharmacogenetics could represent additional risk factors in IAA abuse.
<fig id="Fig9"><label>Fig.&#x000a0;9</label><caption><p>Serotonergic neurotransmission. Hyperserotonergic effects may be induced when a tryptamine derivative (5-HT receptor agonist) and a &#x003b2;-carboline (monoamine oxidase inhibitor) are used concurrently. In particular, the &#x003b2;-carboline can reduce the degradation of 5-HT neurotransmitter and inhibit the metabolism of tryptamine derivative</p></caption><graphic xlink:href="12248_2008_9028_Fig9_HTML" id="MO9"/></fig></p><p>The dominant role of CYP2D6 in ibogaine O-demethylation metabolism also suggests that ibogaine may be subject to metabolic DDIs with CYP2D6 inhibitors (<xref ref-type="bibr" rid="CR93">93</xref>). Of note, some selective serotonin reuptake inhibitors (SSRIs) such as paroxetine and fluoxetine are potent inhibitors of CYP2D6. These SSRIs have been known to cause DDIs with other psychotropic drugs metabolized by CYP2D6. Quinidine is another known potent inhibitor of CYP2D6 with an inhibitory potency in the nanomolar range. A single oral dose of 50&#x000a0;mg of quinidine strikingly altered the metabolism and disposition of CYP2D6 substrate drugs including debrisoquine, dextromethorphan and codeine (<xref ref-type="bibr" rid="CR94">94</xref>&#x02013;<xref ref-type="bibr" rid="CR96">96</xref>). Similarly, the potential of metabolic DDIs is increased (<xref ref-type="bibr" rid="CR93">93</xref>) for ibogaine with CYP2D6 inhibitory medications including SSRIs.</p><p>Nevertheless, quantitative prediction of DDIs with IAA drugs of abuse is extremely difficult because the precise contribution of specific drug-metabolizing enzyme to the overall clearance of an IAA drug (e.g. 5-MeO-DMT) or even the enzymes involved (e.g. LSD) remains unknown. Secondly, other factors including drug transporters and/or the target receptors or enzymes may be affected simultaneously by the drugs. Thus, theoretical predictions of DDIs with IAA drugs can be quite complex, and would require clinical verification.</p></sec></sec><sec id="Sec13"><title>CONCLUSION</title><p>Acting on the serotonergic system, IAA drugs represent a major class of abused hallucinogens. Some IAA drugs however show potential in psychopharmacotherapy and others have been developed as antimigraine agents. Studies on the metabolism of triptans provide useful information to predict adverse metabolic DDIs in clinical practice. In contrast, there are limited metabolic data for IAA drugs of abuse. Increased knowledge in this area could provide better understanding of the hazards of IAA drugs of abuse, including the potential of metabolic variability and adverse interactions with other abused or therapeutic drugs.</p></sec></body><back><ack><title>Acknowledgements</title><p>The project described was supported by Grant number R01DA021172 from the National Institute on Drug Abuse. The author also thanks Drs. Ho-Leung Fung and Robert M. Straubinger for their helpful suggestions and discussions.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>S. D.</given-names></name><name><surname>McCrory</surname><given-names>D. C.</given-names></name></person-group><article-title>Ergotamine and dihydroergotamine: history, pharmacology, and efficacy</article-title><source>Headache</source><year>2003</year><volume>43</volume><issue>2</issue><fpage>144</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2003.03034.x</pub-id><pub-id pub-id-type="pmid">12558771</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jhee</surname><given-names>S. S.</given-names></name><name><surname>Shiovitz</surname><given-names>T.</given-names></name><name><surname>Crawford</surname><given-names>A. W.</given-names></name><name><surname>Cutler</surname><given-names>N. R.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review</article-title><source>Clin. Pharmacokinet.</source><year>2001</year><volume>40</volume><issue>3</issue><fpage>189</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.2165/00003088-200140030-00004</pub-id><pub-id pub-id-type="pmid">11327198</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlof</surname><given-names>C.</given-names></name></person-group><article-title>Integrating the triptans into clinical practice</article-title><source>Curr. Opin. Neurol.</source><year>2002</year><volume>15</volume><issue>3</issue><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1097/00019052-200206000-00015</pub-id><pub-id pub-id-type="pmid">12045731</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shulgin</surname><given-names>A. T.</given-names></name><name><surname>Shulgin</surname><given-names>A.</given-names></name></person-group><source>TIKAL The Continuation</source><year>1997</year><publisher-loc>Berkeley, CA</publisher-loc><publisher-name>Transform</publisher-name></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>G. K.</given-names></name><name><surname>Marek</surname><given-names>G. J.</given-names></name></person-group><article-title>Serotonin and hallucinogens</article-title><source>Neuropsychopharmacology</source><year>1999</year><volume>21</volume><issue>2 Suppl</issue><fpage>16S</fpage><lpage>23S</lpage><pub-id pub-id-type="pmid">10432484</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glennon</surname><given-names>R. A.</given-names></name></person-group><article-title>Arylalkylamine drugs of abuse: an overview of drug discrimination studies</article-title><source>Pharmacol. Biochem. Behav.</source><year>1999</year><volume>64</volume><issue>2</issue><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(99)00045-3</pub-id><pub-id pub-id-type="pmid">10515299</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brush</surname><given-names>D. E.</given-names></name><name><surname>Bird</surname><given-names>S. B.</given-names></name><name><surname>Boyer</surname><given-names>E. W.</given-names></name></person-group><article-title>Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>2004</year><volume>42</volume><issue>2</issue><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">15214625</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>H.</given-names></name><name><surname>Nelson</surname><given-names>L. S.</given-names></name><name><surname>Hoffman</surname><given-names>R. S.</given-names></name></person-group><article-title>Alpha-methyltryptamine revisited via easy Internet access</article-title><source>Vet. Hum. Toxicol.</source><year>2003</year><volume>45</volume><issue>3</issue><fpage>149</fpage><pub-id pub-id-type="pmid">12776793</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>A. A.</given-names></name></person-group><article-title>New drugs of abuse update: Foxy Methoxy</article-title><source>J. Emerg. Nurs.</source><year>2004</year><volume>30</volume><issue>5</issue><fpage>507</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/j.jen.2004.07.037</pub-id><pub-id pub-id-type="pmid">15452541</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>E. W.</given-names></name><name><surname>Shannon</surname><given-names>M.</given-names></name></person-group><article-title>The serotonin syndrome</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>352</volume><issue>11</issue><fpage>1112</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1056/NEJMra041867</pub-id><pub-id pub-id-type="pmid">15784664</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isbister</surname><given-names>G. K.</given-names></name><name><surname>Buckley</surname><given-names>N. A.</given-names></name></person-group><article-title>The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment</article-title><source>Clin. Neuropharmacol.</source><year>2005</year><volume>28</volume><issue>5</issue><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1097/01.wnf.0000177642.89888.85</pub-id><pub-id pub-id-type="pmid">16239759</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agurell</surname><given-names>S.</given-names></name><name><surname>Holmstedt</surname><given-names>B.</given-names></name><name><surname>Lindgren</surname><given-names>J. E.</given-names></name></person-group><article-title>Metabolism of 5-methoxy-N,-N dimethyltryptamine-14 C in the rat</article-title><source>Biochem. Pharmacol.</source><year>1969</year><volume>18</volume><issue>10</issue><fpage>2771</fpage><lpage>2781</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(69)90185-3</pub-id><pub-id pub-id-type="pmid">5404007</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitaram</surname><given-names>B. R.</given-names></name><name><surname>Lockett</surname><given-names>L.</given-names></name><name><surname>Talomsin</surname><given-names>R.</given-names></name><name><surname>Blackman</surname><given-names>G. L.</given-names></name><name><surname>McLeod</surname><given-names>W. R.</given-names></name></person-group><article-title><italic>In vivo</italic> metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat</article-title><source>Biochem. Pharmacol.</source><year>1987</year><volume>36</volume><issue>9</issue><fpage>1509</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(87)90118-3</pub-id><pub-id pub-id-type="pmid">3472526</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guengerich</surname><given-names>F. P.</given-names></name></person-group><article-title>2 in drug metabolism and toxicity</article-title><source>AAPS J.</source><year>2006</year><volume>8</volume><issue>1</issue><fpage>E101</fpage><lpage>E111</lpage><pub-id pub-id-type="doi">10.1208/aapsj080112</pub-id><pub-id pub-id-type="pmid">16584116</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>J. L.</given-names></name></person-group><article-title>Symbiotic relationship of pharmacogenetics and drugs of abuse</article-title><source>AAPS J</source><year>2006</year><volume>8</volume><issue>1</issue><fpage>E174</fpage><lpage>E184</lpage><pub-id pub-id-type="doi">10.1208/aapsj080121</pub-id><pub-id pub-id-type="pmid">16584126</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>P.</given-names></name><name><surname>Saxena</surname><given-names>P. R.</given-names></name><name><surname>Dahlof</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Ergotamine in the acute treatment of migraine: a review and European consensus</article-title><source>Brain</source><year>2000</year><volume>123</volume><issue>Pt 1</issue><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1093/brain/123.1.9</pub-id><pub-id pub-id-type="pmid">10611116</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moubarak</surname><given-names>A. S.</given-names></name><name><surname>Rosenkrans</surname><given-names>C. F. </given-names></name></person-group><article-title>Hepatic metabolism of ergot alkaloids in beef cattle by cytochrome P450</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2000</year><volume>274</volume><issue>3</issue><fpage>746</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.3210</pub-id><pub-id pub-id-type="pmid">10924348</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>C. M.</given-names></name><name><surname>Park</surname><given-names>G. R.</given-names></name><name><surname>Tarbit</surname><given-names>M. H.</given-names></name></person-group><article-title>Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver</article-title><source>Biochem. Pharmacol.</source><year>1994</year><volume>47</volume><issue>7</issue><fpage>1253</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(94)90397-2</pub-id><pub-id pub-id-type="pmid">8161354</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vyas</surname><given-names>K. P.</given-names></name><name><surname>Halpin</surname><given-names>R. A.</given-names></name><name><surname>Geer</surname><given-names>L. A.</given-names></name><etal/></person-group><article-title>Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans</article-title><source>Drug Metab. Dispos.</source><year>2000</year><volume>28</volume><issue>1</issue><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">10611145</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleishaker</surname><given-names>J. C.</given-names></name><name><surname>Ryan</surname><given-names>K. K.</given-names></name><name><surname>Jansat</surname><given-names>J. M.</given-names></name><etal/></person-group><article-title>Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans</article-title><source>Br. J. Clin. Pharmacol.</source><year>2001</year><volume>51</volume><issue>5</issue><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2001.01367.x</pub-id><pub-id pub-id-type="pmid">11422001</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>M. J.</given-names></name><name><surname>McKillop</surname><given-names>D.</given-names></name><name><surname>Butters</surname><given-names>C. J.</given-names></name></person-group><article-title>Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan</article-title><source>Xenobiotica</source><year>1999</year><volume>29</volume><issue>8</issue><fpage>847</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1080/004982599238290</pub-id><pub-id pub-id-type="pmid">10553725</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>P.</given-names></name><name><surname>Wade</surname><given-names>A.</given-names></name><name><surname>Ward</surname><given-names>C.</given-names></name><name><surname>Oliver</surname><given-names>S. D.</given-names></name><name><surname>Stewart</surname><given-names>A. J.</given-names></name><name><surname>Freestone</surname><given-names>S.</given-names></name></person-group><article-title>Frovatriptan: a review of drug&#x02013;drug interactions</article-title><source>Headache</source><year>2002</year><volume>42</volume><issue>Suppl 2</issue><fpage>S63</fpage><lpage>S73</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.42.s2.4.x</pub-id><pub-id pub-id-type="pmid">12028322</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>P.</given-names></name><name><surname>Keywood</surname><given-names>C.</given-names></name><name><surname>Wade</surname><given-names>A.</given-names></name><name><surname>Ward</surname><given-names>C.</given-names></name></person-group><article-title>Clinical pharmacokinetics of frovatriptan</article-title><source>Headache</source><year>2002</year><volume>42</volume><issue>Suppl 2</issue><fpage>S54</fpage><lpage>S62</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.42.s2.3.x</pub-id><pub-id pub-id-type="pmid">12028321</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>D. C.</given-names></name><name><surname>O'Connor</surname><given-names>D.</given-names></name><name><surname>Lake</surname><given-names>B. G.</given-names></name><name><surname>Evers</surname><given-names>R.</given-names></name><name><surname>Allen</surname><given-names>C.</given-names></name><name><surname>Hargreaves</surname><given-names>R.</given-names></name></person-group><article-title>Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein</article-title><source>Drug Metab. Dispos.</source><year>2003</year><volume>31</volume><issue>7</issue><fpage>861</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1124/dmd.31.7.861</pub-id><pub-id pub-id-type="pmid">12814962</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolan</surname><given-names>P.</given-names></name></person-group><article-title>Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90)</article-title><source>Cephalalgia</source><year>1997</year><volume>17</volume><issue>Suppl 18</issue><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">9399014</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>J.</given-names></name></person-group><article-title>Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine</article-title><source>J. Psychoactive Drugs</source><year>2001</year><volume>33</volume><issue>3</issue><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">11718320</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>J.</given-names></name></person-group><article-title>Pharmepena-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine</article-title><source>J. Psychoactive Drugs</source><year>2001</year><volume>33</volume><issue>4</issue><fpage>403</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">11824699</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>D. J.</given-names></name></person-group><article-title>Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges</article-title><source>Pharmacol. Ther.</source><year>2004</year><volume>102</volume><issue>2</issue><fpage>111</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2004.03.002</pub-id><pub-id pub-id-type="pmid">15163593</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narasimhachari</surname><given-names>N.</given-names></name><name><surname>Heller</surname><given-names>B.</given-names></name><name><surname>Spaide</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Urinary studies of schizophrenics and controls</article-title><source>Biol. Psychiatry</source><year>1971</year><volume>3</volume><issue>1</issue><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">4398666</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guchhait</surname><given-names>R. B.</given-names></name></person-group><article-title>Biogenesis of 5-methoxy-N,N-dimethyltryptamine in human pineal gland</article-title><source>J. Neurochem.</source><year>1976</year><volume>26</volume><issue>1</issue><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">1255170</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Airaksinen</surname><given-names>M. M.</given-names></name><name><surname>Kari</surname><given-names>I.</given-names></name></person-group><article-title>Beta-carbolines, psychoactive compounds in the mammalian body. Part I: occurrence, origin and metabolism</article-title><source>Med. Biol.</source><year>1981</year><volume>59</volume><issue>1</issue><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">7022042</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leino</surname><given-names>M.</given-names></name><name><surname>Airaksinen</surname><given-names>M. M.</given-names></name></person-group><article-title>Methoxyindoles of the retina</article-title><source>Med. Biol.</source><year>1985</year><volume>63</volume><issue>4</issue><fpage>160</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">2419712</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>A. M.</given-names></name><name><surname>Idle</surname><given-names>J. R.</given-names></name><name><surname>Herraiz</surname><given-names>T.</given-names></name><name><surname>Kupfer</surname><given-names>A.</given-names></name><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name></person-group><article-title>Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase</article-title><source>Pharmacogenetics</source><year>2003</year><volume>13</volume><issue>6</issue><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1097/00008571-200306000-00002</pub-id><pub-id pub-id-type="pmid">12777961</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>N.</given-names></name><name><surname>Ikeda</surname><given-names>R.</given-names></name><name><surname>Ohba</surname><given-names>K.</given-names></name><name><surname>Kondo</surname><given-names>M.</given-names></name></person-group><article-title>Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders</article-title><source>Neuroreport</source><year>1995</year><volume>6</volume><issue>17</issue><fpage>2378</fpage><lpage>2380</lpage><pub-id pub-id-type="doi">10.1097/00001756-199511270-00024</pub-id><pub-id pub-id-type="pmid">8747157</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">L. D. Johnston, P. M. O'Malley, J. G. Bachman, and J. E. Schulenberg. <italic>Teen Drug Use Continues Down in 2006, Particularly Among Older Teens; But Use of Prescription-type Drugs Remains High</italic>. University of Michigan News and Information Services, Ann Arbor, MI, December 21, 2006. Available: <ext-link ext-link-type="uri" xlink:href="http://www.monitoringthefuture.org">www.monitoringthefuture.org</ext-link>.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mash</surname><given-names>D. C.</given-names></name><name><surname>Kovera</surname><given-names>C. A.</given-names></name><name><surname>Pablo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures</article-title><source>Ann. NY Acad. Sci.</source><year>2000</year><volume>914</volume><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">11085338</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>B. L.</given-names></name><name><surname>Hanizavareh</surname><given-names>S. M.</given-names></name><name><surname>Blum</surname><given-names>A. E.</given-names></name></person-group><article-title>Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders</article-title><source>Psychopharmacology (Berl.)</source><year>2004</year><volume>174</volume><issue>1</issue><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s00213-003-1683-8</pub-id><pub-id pub-id-type="pmid">15205874</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>H. D.</given-names></name><name><surname>Aldridge</surname><given-names>A. M.</given-names></name><name><surname>Gogia</surname><given-names>P.</given-names></name></person-group><article-title>The psychopharmacology of hallucinogens</article-title><source>Neuropsychopharmacology</source><year>1996</year><volume>14</volume><issue>4</issue><fpage>285</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/0893-133X(95)00136-2</pub-id><pub-id pub-id-type="pmid">8924196</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>H. D.</given-names></name><name><surname>Aldridge</surname><given-names>A. M.</given-names></name></person-group><article-title>Adverse consequences of lysergic acid diethylamide</article-title><source>Addiction</source><year>1993</year><volume>88</volume><issue>10</issue><fpage>1327</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.1993.tb02018.x</pub-id><pub-id pub-id-type="pmid">8251869</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glennon</surname><given-names>R. A.</given-names></name><name><surname>Titeler</surname><given-names>M.</given-names></name><name><surname>McKenney</surname><given-names>J. D.</given-names></name></person-group><article-title>Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents</article-title><source>Life Sci.</source><year>1984</year><volume>35</volume><issue>25</issue><fpage>2505</fpage><lpage>2511</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(84)90436-3</pub-id><pub-id pub-id-type="pmid">6513725</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>J. C.</given-names></name><name><surname>Fiorella</surname><given-names>D. J.</given-names></name><name><surname>Timineri</surname><given-names>D. M.</given-names></name><name><surname>Filipink</surname><given-names>R. A.</given-names></name><name><surname>Helsley</surname><given-names>S. E.</given-names></name><name><surname>Rabin</surname><given-names>R. A.</given-names></name></person-group><article-title>Serotonergic receptor subtypes and hallucinogen-induced stimulus control</article-title><source>Pharmacol. Biochem. Behav.</source><year>1999</year><volume>64</volume><issue>2</issue><fpage>283</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(99)00063-5</pub-id><pub-id pub-id-type="pmid">10515304</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Airaksinen</surname><given-names>M. M.</given-names></name><name><surname>Kari</surname><given-names>I.</given-names></name></person-group><article-title>beta-Carbolines, psychoactive compounds in the mammalian body. Part II: Effects</article-title><source>Med. Biol.</source><year>1981</year><volume>59</volume><issue>4</issue><fpage>190</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">6121956</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Fattah</surname><given-names>A. F.</given-names></name><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Gammaz</surname><given-names>H. A.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name></person-group><article-title>Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism</article-title><source>Pharmacol. Biochem. Behav.</source><year>1995</year><volume>52</volume><issue>2</issue><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(95)00131-F</pub-id><pub-id pub-id-type="pmid">8577810</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutes</surname><given-names>J.</given-names></name><name><surname>Lorden</surname><given-names>J. F.</given-names></name><name><surname>Beales</surname><given-names>M.</given-names></name><name><surname>Oltmans</surname><given-names>G. A.</given-names></name></person-group><article-title>Tolerance to the tremorogenic effects of harmaline: evidence for altered olivo-cerebellar function</article-title><source>Neuropharmacology</source><year>1988</year><volume>27</volume><issue>8</issue><fpage>849</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1016/0028-3908(88)90102-5</pub-id><pub-id pub-id-type="pmid">2851115</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husbands</surname><given-names>S. M.</given-names></name><name><surname>Glennon</surname><given-names>R. A.</given-names></name><name><surname>Gorgerat</surname><given-names>S.</given-names></name><etal/></person-group><article-title>beta-carboline binding to imidazoline receptors</article-title><source>Drug Alcohol Depend.</source><year>2001</year><volume>64</volume><issue>2</issue><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S0376-8716(01)00123-5</pub-id><pub-id pub-id-type="pmid">11543990</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glennon</surname><given-names>R. A.</given-names></name><name><surname>Dukat</surname><given-names>M.</given-names></name><name><surname>Grella</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors</article-title><source>Drug Alcohol Depend.</source><year>2000</year><volume>60</volume><issue>2</issue><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/S0376-8716(99)00148-9</pub-id><pub-id pub-id-type="pmid">10940539</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Durantez</surname><given-names>E.</given-names></name><name><surname>Ruiz-Ortega</surname><given-names>J. A.</given-names></name><name><surname>Pineda</surname><given-names>J.</given-names></name><name><surname>Ugedo</surname><given-names>L.</given-names></name></person-group><article-title>Stimulatory effect of harmane and other beta-carbolines on locus coeruleus neurons in anaesthetized rats</article-title><source>Neurosci. Lett.</source><year>2001</year><volume>308</volume><issue>3</issue><fpage>197</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(01)02010-9</pub-id><pub-id pub-id-type="pmid">11479022</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ator</surname><given-names>N. A.</given-names></name><name><surname>Grant</surname><given-names>K. A.</given-names></name><name><surname>Purdy</surname><given-names>R. H.</given-names></name><name><surname>Paul</surname><given-names>S. M.</given-names></name><name><surname>Griffiths</surname><given-names>R. R.</given-names></name></person-group><article-title>Drug discrimination analysis of endogenous neuroactive steroids in rats</article-title><source>Eur. J. Pharmacol.</source><year>1993</year><volume>241</volume><issue>2&#x02013;3</issue><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(93)90208-Y</pub-id><pub-id pub-id-type="pmid">7902289</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>C. R.</given-names></name><name><surname>Johanson</surname><given-names>C. E.</given-names></name></person-group><article-title>Relationship between the discriminative stimulus properties and subjective effects of drugs</article-title><source>Psychopharmacol. Ser.</source><year>1988</year><volume>4</volume><fpage>161</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">3293041</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brauer</surname><given-names>L. H.</given-names></name><name><surname>Goudie</surname><given-names>A. J.</given-names></name><name><surname>Wit</surname><given-names>H.</given-names></name></person-group><article-title>Dopamine ligands and the stimulus effects of amphetamine animal models <italic>versus</italic> human laboratory data</article-title><source>Psychopharmacology (Berl.)</source><year>1997</year><volume>130</volume><issue>1</issue><fpage>2</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s002130050207</pub-id><pub-id pub-id-type="pmid">9089844</pub-id></mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dekeyne</surname><given-names>A.</given-names></name><name><surname>Millan</surname><given-names>M. J.</given-names></name></person-group><article-title>Discriminative stimulus properties of antidepressant agents: a review</article-title><source>Behav. Pharmacol.</source><year>2003</year><volume>14</volume><issue>5&#x02013;6</issue><fpage>391</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">14501253</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudelsky</surname><given-names>G. A.</given-names></name><name><surname>Koenig</surname><given-names>J. I.</given-names></name><name><surname>Jackman</surname><given-names>H.</given-names></name><name><surname>Meltzer</surname><given-names>H. Y.</given-names></name></person-group><article-title>Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors</article-title><source>Psychopharmacology (Berl.)</source><year>1986</year><volume>90</volume><issue>3</issue><fpage>403</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1007/BF00179199</pub-id><pub-id pub-id-type="pmid">2947256</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudelsky</surname><given-names>G. A.</given-names></name><name><surname>Koenig</surname><given-names>J. I.</given-names></name><name><surname>Meltzer</surname><given-names>H. Y.</given-names></name></person-group><article-title>Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors</article-title><source>Neuropharmacology</source><year>1986</year><volume>25</volume><issue>12</issue><fpage>1307</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1016/0028-3908(86)90101-2</pub-id><pub-id pub-id-type="pmid">2951611</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddik</surname><given-names>Z. H.</given-names></name><name><surname>Barnes</surname><given-names>R. D.</given-names></name><name><surname>Dring</surname><given-names>L. G.</given-names></name><name><surname>Smith</surname><given-names>R. L.</given-names></name><name><surname>Williams</surname><given-names>R. T.</given-names></name></person-group><article-title>The fate of lysergic acid DI[14C]ethylamide ([14C]LSD) in the rat, guinea pig and rhesus monkey and of [14C]iso-LSD in rat</article-title><source>Biochem. Pharmacol.</source><year>1979</year><volume>28</volume><issue>20</issue><fpage>3093</fpage><lpage>3101</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(79)90618-X</pub-id><pub-id pub-id-type="pmid">117811</pub-id></mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddik</surname><given-names>Z. H.</given-names></name><name><surname>Barnes</surname><given-names>R. D.</given-names></name><name><surname>Dring</surname><given-names>L. G.</given-names></name><name><surname>Smith</surname><given-names>R. L.</given-names></name><name><surname>Williams</surname><given-names>R. T.</given-names></name></person-group><article-title>The metabolism of lysergic acid DI[14C]ethylamide ([14C]LSD) in the isolated perfused rat liver</article-title><source>Biochem. Pharmacol.</source><year>1979</year><volume>28</volume><issue>20</issue><fpage>3081</fpage><lpage>3091</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(79)90617-8</pub-id><pub-id pub-id-type="pmid">518707</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Niwaguchi</surname><given-names>T.</given-names></name><name><surname>Murata</surname><given-names>T.</given-names></name></person-group><article-title>Enzymic formation of dehydrogenated and hydroxylated metabolites from lysergic acid diethylamide by rat liver microsomes</article-title><source>Xenobiotica</source><year>1980</year><volume>10</volume><issue>5</issue><fpage>343</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">7415216</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuschel</surname><given-names>S. A.</given-names></name><name><surname>Eades</surname><given-names>D.</given-names></name><name><surname>Foltz</surname><given-names>R. L.</given-names></name></person-group><article-title>Recent advances in chromatographic and mass spectrometric methods for determination of LSD and its metabolites in physiological specimens</article-title><source>J. Chromatogr. B. Biomed. Sci. Appl.</source><year>1999</year><volume>733</volume><issue>1&#x02013;2</issue><fpage>145</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/S0378-4347(99)00189-9</pub-id><pub-id pub-id-type="pmid">10572980</pub-id></mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Henion</surname><given-names>J.</given-names></name></person-group><article-title>Elucidation of LSD <italic>in vitro</italic> metabolism by liquid chromatography and capillary electrophoresis coupled with tandem mass spectrometry</article-title><source>J. Anal. Toxicol.</source><year>1996</year><volume>20</volume><issue>1</issue><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">8837948</pub-id></mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstraete</surname><given-names>A. G.</given-names></name><name><surname>Velde</surname><given-names>E. J.</given-names></name></person-group><article-title>2-oxo-3-hydroxy-LSD: an important LSD metabolite?</article-title><source>Acta. Clin. Belg. Suppl.</source><year>1999</year><volume>1</volume><fpage>94</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">10216992</pub-id></mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klette</surname><given-names>K. L.</given-names></name><name><surname>Anderson</surname><given-names>C. J.</given-names></name><name><surname>Poch</surname><given-names>G. K.</given-names></name><name><surname>Nimrod</surname><given-names>A. C.</given-names></name><name><surname>ElSohly</surname><given-names>M. A.</given-names></name></person-group><article-title>Metabolism of lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (O-H-LSD) in human liver microsomes and cryopreserved human hepatocytes</article-title><source>J. Anal. Toxicol.</source><year>2000</year><volume>24</volume><issue>7</issue><fpage>550</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">11043658</pub-id></mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>A. M.</given-names></name><name><surname>Granvil</surname><given-names>C. P.</given-names></name><name><surname>Haining</surname><given-names>R. L.</given-names></name><etal/></person-group><article-title>The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine</article-title><source>J Pharmacol. Exp. Ther.</source><year>2003</year><volume>304</volume><issue>2</issue><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1124/jpet.102.043786</pub-id><pub-id pub-id-type="pmid">12538805</pub-id></mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynaud</surname><given-names>F.</given-names></name><name><surname>Pevet</surname><given-names>P.</given-names></name></person-group><article-title>5-Methoxytryptamine is metabolized by monoamine oxidase A in the pineal gland and plasma of golden hamsters</article-title><source>Neurosci. Lett.</source><year>1991</year><volume>123</volume><issue>2</issue><fpage>172</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(91)90923-H</pub-id><pub-id pub-id-type="pmid">2027530</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>O.</given-names></name><name><surname>Katsumata</surname><given-names>Y.</given-names></name><name><surname>Oya</surname><given-names>M.</given-names></name></person-group><article-title>Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase</article-title><source>Biochem. Pharmacol.</source><year>1981</year><volume>30</volume><issue>11</issue><fpage>1353</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(81)90300-2</pub-id><pub-id pub-id-type="pmid">6791651</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>R. W.</given-names></name><name><surname>Snoddy</surname><given-names>H. D.</given-names></name><name><surname>Perry</surname><given-names>K. W.</given-names></name></person-group><article-title>Tissue distribution, metabolism and effects of bufotenine administered to rats</article-title><source>Neuropharmacology</source><year>1995</year><volume>34</volume><issue>7</issue><fpage>799</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1016/0028-3908(95)00049-C</pub-id><pub-id pub-id-type="pmid">8532147</pub-id></mixed-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szara</surname><given-names>S.</given-names></name><name><surname>Axelrod</surname><given-names>J.</given-names></name></person-group><article-title>Hydroxylation and N-demethylation of N, N-dimethyltryptamine</article-title><source>Experientia</source><year>1959</year><volume>15</volume><issue>6</issue><fpage>216</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/BF02158111</pub-id><pub-id pub-id-type="pmid">13672176</pub-id></mixed-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders-Bush</surname><given-names>E.</given-names></name><name><surname>Oates</surname><given-names>J. A.</given-names></name><name><surname>Bush</surname><given-names>M. T.</given-names></name></person-group><article-title>Metabolism of bufotenine-2&#x000a2;-14C in human volunteers</article-title><source>Life Sci.</source><year>1976</year><volume>19</volume><issue>9</issue><fpage>1407</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(76)90441-0</pub-id><pub-id pub-id-type="pmid">994734</pub-id></mixed-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitaram</surname><given-names>B. R.</given-names></name><name><surname>Lockett</surname><given-names>L.</given-names></name><name><surname>Blackman</surname><given-names>G. L.</given-names></name><name><surname>McLeod</surname><given-names>W. R.</given-names></name></person-group><article-title>Urinary excretion of 5-methoxy-N,N-dimethyltryptamine, N,N-dimethyltryptamine and their N-oxides in the rat</article-title><source>Biochem. Pharmacol.</source><year>1987</year><volume>36</volume><issue>13</issue><fpage>2235</fpage><lpage>2237</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(87)90159-6</pub-id><pub-id pub-id-type="pmid">3475068</pub-id></mixed-citation></ref><ref id="CR68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitaram</surname><given-names>B. R.</given-names></name><name><surname>Talomsin</surname><given-names>R.</given-names></name><name><surname>Blackman</surname><given-names>G. L.</given-names></name><name><surname>McLeod</surname><given-names>W. R.</given-names></name></person-group><article-title>Study of metabolism of psychotomimetic indolealkylamines by rat tissue extracts using liquid chromatography</article-title><source>Biochem. Pharmacol.</source><year>1987</year><volume>36</volume><issue>9</issue><fpage>1503</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(87)90117-1</pub-id><pub-id pub-id-type="pmid">3472525</pub-id></mixed-citation></ref><ref id="CR69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>A. M.</given-names></name><name><surname>Idle</surname><given-names>J. R.</given-names></name><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name></person-group><article-title>Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates</article-title><source>Drug Metab. Rev.</source><year>2004</year><volume>36</volume><issue>2</issue><fpage>243</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1081/DMR-120034000</pub-id><pub-id pub-id-type="pmid">15237854</pub-id></mixed-citation></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanger</surname><given-names>U. M.</given-names></name><name><surname>Raimundo</surname><given-names>S.</given-names></name><name><surname>Eichelbaum</surname><given-names>M.</given-names></name></person-group><article-title>Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry</article-title><source>Naunyn. Schmiedebergs. Arch. Pharmacol.</source><year>2004</year><volume>369</volume><issue>1</issue><fpage>23</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s00210-003-0832-2</pub-id><pub-id pub-id-type="pmid">14618296</pub-id></mixed-citation></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>M. C.</given-names></name></person-group><article-title>Bufotenine: toward an understanding of possible psychoactive mechanisms</article-title><source>J. Psychoactive Drugs</source><year>2000</year><volume>32</volume><issue>3</issue><fpage>321</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">11061684</pub-id></mixed-citation></ref><ref id="CR72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>B. L.</given-names></name><name><surname>Choudhary</surname><given-names>M. S.</given-names></name><name><surname>Khan</surname><given-names>N.</given-names></name><name><surname>Uluer</surname><given-names>A. Z.</given-names></name></person-group><article-title>High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1997</year><volume>280</volume><issue>2</issue><fpage>576</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">9023266</pub-id></mixed-citation></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>W. H.</given-names></name><name><surname>Evans</surname><given-names>B. D.</given-names></name></person-group><article-title>Structure&#x02013;activity-relationships of certain hallucinogenic substances based on brain levels</article-title><source>Life Sci.</source><year>1977</year><volume>20</volume><issue>10</issue><fpage>1629</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(77)90335-6</pub-id><pub-id pub-id-type="pmid">69244</pub-id></mixed-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamata</surname><given-names>T.</given-names></name><name><surname>Katagi</surname><given-names>M.</given-names></name><name><surname>Kamata</surname><given-names>H. T.</given-names></name><etal/></person-group><article-title>Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites</article-title><source>Drug Metab. Dispos.</source><year>2006</year><volume>34</volume><issue>2</issue><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1124/dmd.105.005835</pub-id><pub-id pub-id-type="pmid">16280455</pub-id></mixed-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meatherall</surname><given-names>R.</given-names></name><name><surname>Sharma</surname><given-names>P.</given-names></name></person-group><article-title>Foxy, a designer tryptamine hallucinogen</article-title><source>J. Anal. Toxicol.</source><year>2003</year><volume>27</volume><issue>5</issue><fpage>313</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">12908946</pub-id></mixed-citation></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>J. M.</given-names></name><name><surname>McGeorge</surname><given-names>F.</given-names></name><name><surname>Smolinske</surname><given-names>S.</given-names></name><name><surname>Meatherall</surname><given-names>R.</given-names></name></person-group><article-title>A foxy intoxication</article-title><source>Forensic Sci. Int.</source><year>2005</year><volume>148</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2004.04.017</pub-id><pub-id pub-id-type="pmid">15607587</pub-id></mixed-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>E.</given-names></name><name><surname>Kamata</surname><given-names>T.</given-names></name><name><surname>Katagi</surname><given-names>M.</given-names></name><name><surname>Tsuchihashi</surname><given-names>H.</given-names></name><name><surname>Honda</surname><given-names>K.</given-names></name></person-group><article-title>A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy</article-title><source>Forensic Sci. Int.</source><year>2006</year><volume>163</volume><issue>1&#x02013;2</issue><fpage>152</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2005.11.026</pub-id><pub-id pub-id-type="pmid">16406422</pub-id></mixed-citation></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narimatsu</surname><given-names>S.</given-names></name><name><surname>Yonemoto</surname><given-names>R.</given-names></name><name><surname>Masuda</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Oxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes</article-title><source>Biochem. Pharmacol.</source><year>2008</year><volume>75</volume><issue>3</issue><fpage>752</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2007.09.019</pub-id><pub-id pub-id-type="pmid">17980859</pub-id></mixed-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narimatsu</surname><given-names>S.</given-names></name><name><surname>Yonemoto</surname><given-names>R.</given-names></name><name><surname>Saito</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes</article-title><source>Biochem. Pharmacol.</source><year>2006</year><volume>71</volume><issue>9</issue><fpage>1377</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2006.01.015</pub-id><pub-id pub-id-type="pmid">16510126</pub-id></mixed-citation></ref><ref id="CR80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name><name><surname>Yu</surname><given-names>A. M.</given-names></name></person-group><article-title>Cytochrome P450 and xenobiotic receptor humanized mice</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2006</year><volume>46</volume><fpage>41</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.100007</pub-id><pub-id pub-id-type="pmid">16402898</pub-id></mixed-citation></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passie</surname><given-names>T.</given-names></name><name><surname>Seifert</surname><given-names>J.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><name><surname>Emrich</surname><given-names>H. M.</given-names></name></person-group><article-title>The pharmacology of psilocybin</article-title><source>Addict. Biol.</source><year>2002</year><volume>7</volume><issue>4</issue><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1080/1355621021000005937</pub-id><pub-id pub-id-type="pmid">14578010</pub-id></mixed-citation></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gearhart</surname><given-names>D. A.</given-names></name><name><surname>Neafsey</surname><given-names>E. J.</given-names></name><name><surname>Collins</surname><given-names>M. A.</given-names></name></person-group><article-title>Phenylethanolamine N-methyltransferase has beta-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson's disease</article-title><source>Neurochem. Int.</source><year>2002</year><volume>40</volume><issue>7</issue><fpage>611</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/S0197-0186(01)00115-2</pub-id><pub-id pub-id-type="pmid">11900856</pub-id></mixed-citation></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>K.</given-names></name><name><surname>Aoyama</surname><given-names>K.</given-names></name><name><surname>Suno</surname><given-names>M.</given-names></name><name><surname>Awaya</surname><given-names>T.</given-names></name></person-group><article-title>N-Methylation underlying Parkinson&#x02019;s disease</article-title><source>Neurotoxicol. Teratol.</source><year>2002</year><volume>24</volume><issue>5</issue><fpage>593</fpage><pub-id pub-id-type="doi">10.1016/S0892-0362(02)00212-X</pub-id><pub-id pub-id-type="pmid">12200190</pub-id></mixed-citation></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tweedie</surname><given-names>D. J.</given-names></name><name><surname>Burke</surname><given-names>M. D.</given-names></name></person-group><article-title>Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice. Identification and quantitation of two novel harmine metabolites</article-title><source>Drug. Metab. Dispos.</source><year>1987</year><volume>15</volume><issue>1</issue><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">2881762</pub-id></mixed-citation></ref><ref id="CR85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>M. D.</given-names></name><name><surname>Upshall</surname><given-names>D. G.</given-names></name></person-group><article-title>Species and phenobarbitone-induced differences in the kinetic constants of liver microsomal harmine O-demethylation</article-title><source>Xenobiotica.</source><year>1976</year><volume>6</volume><issue>5</issue><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">7043</pub-id></mixed-citation></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>A. M.</given-names></name><name><surname>Idle</surname><given-names>J. R.</given-names></name><name><surname>Krausz</surname><given-names>K. W.</given-names></name><name><surname>Kupfer</surname><given-names>A.</given-names></name><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name></person-group><article-title>Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2003</year><volume>305</volume><issue>1</issue><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1124/jpet.102.047050</pub-id><pub-id pub-id-type="pmid">12649384</pub-id></mixed-citation></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>J. C.</given-names></name></person-group><article-title>Fast and slow metabolizers of Hoasca</article-title><source>J. Psychoactive Drugs</source><year>2005</year><volume>37</volume><issue>2</issue><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">16149329</pub-id></mixed-citation></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tweedie</surname><given-names>D. J.</given-names></name><name><surname>Prough</surname><given-names>R. A.</given-names></name><name><surname>Burke</surname><given-names>M. D.</given-names></name></person-group><article-title>Effects of induction on the metabolism and cytochrome P-450 binding of harman and other beta-carbolines</article-title><source>Xenobiotica</source><year>1988</year><volume>18</volume><issue>7</issue><fpage>785</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">3176517</pub-id></mixed-citation></ref><ref id="CR89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>O.</given-names></name><name><surname>Jernstrom</surname><given-names>B.</given-names></name><name><surname>Martinez</surname><given-names>M.</given-names></name><name><surname>Repke</surname><given-names>D. B.</given-names></name></person-group><article-title><italic>In vitro</italic> study of the aromatic hydroxylation of 1-methyltetrahydro-beta-carboline (methtryptoline) in rat</article-title><source>Chem. Biol. Interact.</source><year>1988</year><volume>65</volume><issue>1</issue><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/0009-2797(88)90034-8</pub-id><pub-id pub-id-type="pmid">3345575</pub-id></mixed-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchiya</surname><given-names>H.</given-names></name><name><surname>Todoriki</surname><given-names>H.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name></person-group><article-title>Metabolic hydroxylation of 1-methyl-1,2,3,4-tetrahydro-beta-carboline in humans</article-title><source>Pharmacol. Biochem. Behav.</source><year>1995</year><volume>52</volume><issue>4</issue><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(95)00048-2</pub-id><pub-id pub-id-type="pmid">8587904</pub-id></mixed-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herraiz</surname><given-names>T.</given-names></name><name><surname>Guillen</surname><given-names>H.</given-names></name><name><surname>Aran</surname><given-names>V. J.</given-names></name><name><surname>Idle</surname><given-names>J. R.</given-names></name><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name></person-group><article-title>Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6</article-title><source>Toxicol. Appl. Pharmacol.</source><year>2006</year><volume>216</volume><issue>3</issue><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2006.06.003</pub-id><pub-id pub-id-type="pmid">16870220</pub-id></mixed-citation></ref><ref id="CR92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mash</surname><given-names>D. C.</given-names></name><name><surname>Staley</surname><given-names>J. K.</given-names></name><name><surname>Baumann</surname><given-names>M. H.</given-names></name><name><surname>Rothman</surname><given-names>R. B.</given-names></name><name><surname>Hearn</surname><given-names>W. L.</given-names></name></person-group><article-title>Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin</article-title><source>Life Sci.</source><year>1995</year><volume>57</volume><issue>3</issue><fpage>PL45</fpage><lpage>PL50</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(95)00273-9</pub-id><pub-id pub-id-type="pmid">7596224</pub-id></mixed-citation></ref><ref id="CR93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obach</surname><given-names>R. S.</given-names></name><name><surname>Pablo</surname><given-names>J.</given-names></name><name><surname>Mash</surname><given-names>D. C.</given-names></name></person-group><article-title>Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine</article-title><source>Drug Metab. Dispos.</source><year>1998</year><volume>26</volume><issue>8</issue><fpage>764</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">9698290</pub-id></mixed-citation></ref><ref id="CR94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayesh</surname><given-names>R.</given-names></name><name><surname>Dawling</surname><given-names>S.</given-names></name><name><surname>Hayler</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers</article-title><source>Chirality</source><year>1991</year><volume>3</volume><issue>1</issue><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1002/chir.530030104</pub-id><pub-id pub-id-type="pmid">2039678</pub-id></mixed-citation></ref><ref id="CR95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmeules</surname><given-names>J.</given-names></name><name><surname>Gascon</surname><given-names>M. P.</given-names></name><name><surname>Dayer</surname><given-names>P.</given-names></name><name><surname>Magistris</surname><given-names>M.</given-names></name></person-group><article-title>Impact of environmental and genetic factors on codeine analgesia</article-title><source>Eur. J. Clin. Pharmacol.</source><year>1991</year><volume>41</volume><issue>1</issue><fpage>23</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/BF00280101</pub-id><pub-id pub-id-type="pmid">1782973</pub-id></mixed-citation></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmeules</surname><given-names>J. A.</given-names></name><name><surname>Oestreicher</surname><given-names>M. K.</given-names></name><name><surname>Piguet</surname><given-names>V.</given-names></name><name><surname>Allaz</surname><given-names>A. F.</given-names></name><name><surname>Dayer</surname><given-names>P.</given-names></name></person-group><article-title>Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1999</year><volume>288</volume><issue>2</issue><fpage>607</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">9918565</pub-id></mixed-citation></ref></ref-list></back></article>